Patent · US Active

Targeting of bone marrow neovasculature

US8679488B2 · kind B2 · utility

3Cited by

3References

9Claims

0Family size

Assignee

PHILOGEN S.P.A. · IT

Inventors

Manuela Kaspar · Brugg, CH
Christoph Schliemann · Zürich, CH
Dario Neri · Zürich, CH

Key dates

Filing date	Aug 2, 2010
Grant date	Mar 25, 2014
Priority date	—
Expiry date	Aug 2, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/64
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.